Cover Image
市場調查報告書

搭配診斷相關合作契約:交易趨勢,企業,財務及預測

Global Companion Diagnostics Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 230289
出版日期 內容資訊 英文 242 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
搭配診斷相關合作契約:交易趨勢,企業,財務及預測 Global Companion Diagnostics Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts
出版日期: 2016年10月05日 內容資訊: 英文 242 Pages
簡介

本報告提供搭配診斷相關合作契約動向分析,彙整搭配診斷相關商務活動概要,主要的契約內容驗證,參照實際契約文件的結果,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 搭配診斷相關交易趨勢

  • 簡介
  • 過去數年的搭配診斷合作
  • 最積極的搭配診斷交易公司
  • 不同的交易型態搭配診斷合作
  • 各治療領域搭配診斷合作
  • 搭配診斷的平均交易條件
    • 交易總額
    • 預付款付款額
    • 目標達成褒獎金
    • 權利金比率

第3章 主要搭配診斷契約

  • 簡介
  • 最高金額契約

第4章 對搭配診斷最積極的交易企業

  • 簡介
  • 對搭配診斷最積極的交易企業
  • 對搭配診斷最積極的合作企業簡介

第5章 搭配診斷契約交易一覽

  • 簡介
  • 搭配診斷契約交易一覽

第6章 搭配診斷契約:各技術類型

第7章 合作資源中心

  • 線上合作
  • 合作趨勢
  • 相關資料

附錄

  • 附錄1:搭配診斷契約(各企業A-Z)
  • 附錄2:搭配診斷契約(各開發階段)
    • 藥物研發
    • 前臨床
    • 階段Ⅰ
    • 階段Ⅱ
    • 階段Ⅲ
    • 法規
    • 上市
    • 處方
  • 附錄3:搭配診斷契約(各類型)
    • 資產購買
    • 轉讓
    • 大型製藥公司的對外授權
    • 共同開發
    • 共同R&D
    • 共同上市
    • 共同促銷
    • CRADA
    • 交叉授權
    • 開發
    • 流通銷售
    • 股票購買
    • 評估
    • 轉讓
    • 合資企業
    • 授權
    • 訴訟
    • 製造
    • 行銷
    • 物質移動
    • 選擇
    • 推銷
    • 研究
    • 協定
    • 衍生公司
    • 輔助許可證
    • 供給
    • 技術轉移
    • 契約解除
    • 保證
  • 附錄4:搭配診斷契約(各治療領域)
  • 附錄5:契約類型定義

關於Wildwood Ventures

Current Partnering Current Agreements CurrentPartnering的發行標題

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2106

The Global Companion Diagnostics Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in companion diagnostics partnering deals
  • Companion diagnostics partnering agreement structure
  • Companion diagnostics partnering contract documents
  • Top companion diagnostics deals by value
  • Most active companion diagnostics dealmakers

The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.

The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 350 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.

Key benefits

Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Companion Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Companion Diagnostics dealmakers since 2010
  • Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Companion Diagnostics trends and structure of deals entered into by leading companies worldwide.

Companion Diagnostics Partnering Terms and Agreements includes:

  • Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010
  • Analysis of Companion Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Companion Diagnostics deals
  • Access to Companion Diagnostics contract documents
  • Leading Companion Diagnostics deals by value since 2010
  • Most active Companion Diagnostics dealmakers since 2010

In Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Companion Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 350 Companion Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Companion Diagnostics Partnering 2010-2016 provides the reader with the following key benefits:

  • In-depth understanding of Companion Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies
  • Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
  • Identify most active Companion Diagnostics dealmakers since 2010
  • Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Companion Diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. Companion Diagnostics partnering over the years
  • 2.3. Most active Companion Diagnostics dealmakers
  • 2.4. Companion Diagnostics partnering by deal type
  • 2.5. Companion Diagnostics partnering by therapy area
  • 2.6. Deal terms for Companion Diagnostics partnering
  • 2.6.1 Companion Diagnostics partnering headline values
  • 2.6.2 Companion Diagnostics deal upfront payments7
  • 2.6.3 Companion Diagnostics deal milestone payments
  • 2.6.4 Companion Diagnostics royalty rates

Chapter 3 - Leading Companion Diagnostics deals

  • 3.1. Introduction
  • 3.2. Top Companion Diagnostics deals by value

Chapter 4 - Most active Companion Diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active Companion Diagnostics dealmakers
  • 4.3. Most active Companion Diagnostics partnering company profiles

Chapter 5 - Companion Diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Companion Diagnostics contracts dealmaking directory

Chapter 6 - Companion Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Companion Diagnostics deals by company A-Z

Appendix 2 - Companion Diagnostics deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Companion Diagnostics deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Companion Diagnostics deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Companion Diagnostics partnering since 2010
  • Figure 2: Active Companion Diagnostics dealmaking activity- 2010 to 2016
  • Figure 3: Companion Diagnostics partnering by deal type since 2010
  • Figure 4: Companion Diagnostics partnering by disease type since 2010
  • Figure 5: Companion Diagnostics deals with a headline value
  • Figure 6: Companion Diagnostics deals with an upfront value
  • Figure 7: Companion Diagnostics deals with a milestone value
  • Figure 8: Companion Diagnostics deals with a royalty rate value
  • Figure 9: Top Companion Diagnostics deals by value since 2010
  • Figure 10: Most active Companion Diagnostics dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top